TLR7 and neoplasm: Resiquimod (R848), a potent TLR7/8 agonist, was used to develop β-cyclodextrin nanoparticles (CDNPs-R848) that induced TAM reprogramming with reduced tumor growth and protection against tumor relapse 226.